Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
Standard
Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors. / Hambach, Julia; Mann, Anna Marei; Bannas, Peter; Koch-Nolte, Friedrich.
in: FRONT IMMUNOL, Jahrgang 13, 1005800, 2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
AU - Hambach, Julia
AU - Mann, Anna Marei
AU - Bannas, Peter
AU - Koch-Nolte, Friedrich
N1 - Copyright © 2022 Hambach, Mann, Bannas and Koch-Nolte.
PY - 2022
Y1 - 2022
N2 - Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.
AB - Nanobodies are well suited for constructing biologics due to their high solubility. We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies. We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors. Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.
KW - Humans
KW - Receptors, Chimeric Antigen/genetics
KW - Multiple Myeloma/drug therapy
KW - Antibodies, Bispecific/therapeutic use
KW - ADP-ribosyl Cyclase 1
KW - Single-Domain Antibodies
KW - Immunoglobulin Heavy Chains/therapeutic use
KW - Killer Cells, Natural
U2 - 10.3389/fimmu.2022.1005800
DO - 10.3389/fimmu.2022.1005800
M3 - SCORING: Review article
C2 - 36405759
VL - 13
JO - FRONT IMMUNOL
JF - FRONT IMMUNOL
SN - 1664-3224
M1 - 1005800
ER -